上海建科：12月15日召开董事会会议

Group 1 - The core point of the article is that Shanghai Jianke announced a board meeting to discuss amendments to the company's salary decision mechanism, with a significant focus on its revenue structure for 2024 [1] - Shanghai Jianke's revenue composition for 2024 is heavily weighted towards professional technical services, accounting for 99.85% of total revenue, while other business segments contribute only 0.15% [1] - As of the latest update, Shanghai Jianke has a market capitalization of 7 billion yuan [2] Group 2 - The article highlights concerns regarding the financial practices of Jiangsu Wuzhong, where significant financial discrepancies have been reported, leading to questions from shareholders about the company's financial integrity [2] - The annual sales of a product referred to as "童颜针" (youthful needle) reached 300 million yuan, raising eyebrows due to the high price point of 2,000 yuan per injection [2] - There are allegations that multiple related parties associated with the product have questionable registration statuses, further complicating the financial situation of Jiangsu Wuzhong [2]